- Home
- RYTM
as of 12-03-2025 3:56pm EST
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 6.4B | IPO Year: | 2017 |
| Target Price: | $118.46 | AVG Volume (30 days): | 684.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $45.91 - $116.00 | Next Earning Date: | 11-04-2025 |
| Revenue: | $174,334,000 | Revenue Growth: | 54.92% |
| Revenue Growth (this year): | 46.1% | Revenue Growth (next year): | 63.02% |
AI-Powered RYTM Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
Chief Human Resources Officer
Avg Cost/Share
$105.00
Shares
3,350
Total Value
$351,750.00
Owned After
20,814
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$100.00
Shares
3,515
Total Value
$351,500.00
Owned After
20,814
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$98.82
Shares
19,351
Total Value
$1,912,325.81
Owned After
20,814
SEC Form 4
Chief Technical Officer
Avg Cost/Share
$115.24
Shares
9,748
Total Value
$1,123,397.54
Owned After
8,509
SEC Form 4
Chief Technical Officer
Avg Cost/Share
$115.01
Shares
2,815
Total Value
$323,750.05
Owned After
8,509
SEC Form 4
Chief Technical Officer
Avg Cost/Share
$111.94
Shares
14,437
Total Value
$1,617,336.82
Owned After
8,509
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Nov 20, 2025 | Sell | $105.00 | 3,350 | $351,750.00 | 20,814 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Nov 10, 2025 | Sell | $100.00 | 3,515 | $351,500.00 | 20,814 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Nov 7, 2025 | Sell | $98.82 | 19,351 | $1,912,325.81 | 20,814 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Oct 30, 2025 | Sell | $115.24 | 9,748 | $1,123,397.54 | 8,509 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Oct 28, 2025 | Sell | $115.01 | 2,815 | $323,750.05 | 8,509 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Oct 16, 2025 | Sell | $111.94 | 14,437 | $1,617,336.82 | 8,509 |
Compare RYTM vs Leading Stocks
See how RYTM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.